Fed Governor Adriana Kugler to resign
On Monday, H.C. Wainwright reaffirmed its Buy rating and $110.00 price target for Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company currently trading at $74.98 with a market capitalization of $5.37 billion. According to InvestingPro data, analyst targets range from $100 to $137, with a strong consensus recommendation of 1.5 (Buy). The firm’s analyst highlighted Nuvalent’s recent implementation of Expanded Access Programs (EAP) for two of its drugs, zidesamtinib and neladalkib, as a positive development. These programs are designed to provide treatments for patients with specific types of non-small cell lung cancer (NSCLC) who have exhausted previous therapies.
Zidesamtinib is now accessible through the EAP for patients with locally advanced or metastatic ROS1-positive NSCLC who have previously undergone ROS1 tyrosine kinase inhibitor (TKI) therapy. Similarly, neladalkib has been made available for those with locally advanced or metastatic ALK-positive NSCLC who have previously been treated with either lorlatinib or a second-generation ALK TKI.
The analyst from H.C. Wainwright noted that the demand to enter clinical trials for these drugs was high, which led to the initiation of the EAPs. These programs are seen as an indication of the need for new treatment options and the readiness of both physicians and patients to consider innovative, though not yet approved, therapies. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 20.96, though it remains unprofitable with negative earnings per share of $3.93.
Furthermore, the analyst believes that the EAPs present a cost-effective strategy for Nuvalent to increase the number of patients receiving treatment with zidesamtinib and neladalkib. This could also help establish a broader prescriber base, potentially leading to a more rapid uptake of the drugs upon receiving regulatory approval.
In conclusion, the firm maintains its positive stance on Nuvalent shares, reiterating the 12-month price target of $110 per share. The EAPs are expected to provide both an immediate means to address patient needs and a foundation for future commercial success upon the drugs’ potential market launch. While the stock shows above-market volatility with a beta of 1.38, InvestingPro analysis suggests the stock is currently overvalued at these levels. Discover more insights and 8 additional ProTips about Nuvalent in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Nuvalent has been in the spotlight following several key developments. H.C. Wainwright reaffirmed its Buy rating for Nuvalent, maintaining a price target of $110, after the company presented its anticipated milestones for 2025, including plans for its first potential FDA approval for zidesamtinib by 2026. The company aims to submit a New Drug Application for zidesamtinib in mid-2025, following promising results from the Phase 1/2 ARROS-1 study. Additionally, Nuvalent is planning to initiate a Phase 3 study named ALKAZAR in 2025 to compare NVL-655 to the standard-of-care treatment.
H.C. Wainwright highlighted the potential impact of Nuvalent’s clinical candidates on the treatment of ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, projecting significant revenue growth upon drug approval and launch. In a separate development, Nuvalent appointed Grant Bogle as an independent director to its board, effective immediately. Bogle will serve until the company’s 2025 annual meeting, with compensation including stock options and restricted stock units. The company also announced a new form of award agreement for restricted stock units with performance-based vesting. These developments reflect Nuvalent’s ongoing efforts to advance its clinical programs and strengthen its governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.